The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2026 | Associations of 9p21 deletions on chemo outcomes in pancreatic ductal adenocarcinoma
Jeremy Kratz, MD, University of Wisconsin Carbone Cancer Center, Madison, WI, presents findings of a study evaluating comprehensive genomic profiling in pancreatic cancer, focusing on CDKN2A/B and MTAP loss (9p21 loci deletion). Emerging PRMT5 inhibitors show promise in early-phase studies. Moving targeted therapies to localized/neoadjuvant settings could improve cure rates by optimizing upfront chemotherapy and potentiating surgical benefits. Biomarkers enable personalized therapy in advanced pancreatic cancer. This interview took place at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
